دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Climate crisis and cancer: the need for urgent action
doi : 10.1016/S1470-2045(21)00534-9
Volume 22, Issue 10, October 2021, Page 1341
Access to and affordability of cancer medicines: time to focus on the last mile
BhawnaSirohiaAjuMathewbc
doi : 10.1016/S1470-2045(21)00518-0
Volume 22, Issue 10, October 2021, Pages 1342-1343
Shortages of essential medications for children with cancer in Colombia
Luz UrcuquiBustamanteaAgustín ContrerasAcostabDiego EstupiñanPericocEdithGrynszpancholcd
doi : 10.1016/S1470-2045(21)00517-9
Volume 22, Issue 10, October 2021, Pages 1343-1345
Daratumumab for post-ASCT maintenance treatment of myeloma
PrashantKapooraShajiKumara
doi : 10.1016/S1470-2045(21)00490-3
Volume 22, Issue 10, October 2021, Pages 1345-1347
CAR T cells for the long run in aggressive B-cell lymphoma
EladJacobyaceAbrahamAvigdorbde
doi : 10.1016/S1470-2045(21)00412-5
Volume 22, Issue 10, October 2021, Pages 1347-1348
Childhood cancer control during the COVID-19 pandemic
SandraLuna-FinemanabRobertaOrtizbAndreIlbawib
doi : 10.1016/S1470-2045(21)00491-5
Volume 22, Issue 10, October 2021, Pages 1348-1350
Anticipating the COVID-19-related surge in cancer care demand is urgent in Latin America and the Caribbean
Cristian AHerreraabPigaFernándezcdAfsanBhadeliaeMauricioMazaf
doi : 10.1016/S1470-2045(21)00484-8
Volume 22, Issue 10, October 2021, Pages 1350-1352
Importance of modelling for cancer management during COVID-19
EnriqueParisa
doi : 10.1016/S1470-2045(21)00408-3
Volume 22, Issue 10, October 2021, Pages 1352-1353
Understanding the new therapeutic options for mesothelioma
Hedy LeeKindlera
doi : 10.1016/S1470-2045(21)00520-9
Volume 22, Issue 10, October 2021, Pages 1353-1355
Surgery versus SABR for early-stage lung cancer—time to call it a draw?
Alexander VLouieaMichael CTjongaShankarSivab
doi : 10.1016/S1470-2045(21)00457-5
Volume 22, Issue 10, October 2021, Pages 1355-1357
Optimal adjuvant endocrine therapy for breast cancer
Rachel LYungaNancy EDavidsona
doi : 10.1016/S1470-2045(21)00420-4
Volume 22, Issue 10, October 2021, Pages 1357-1358
Inappropriate censoring in Kaplan-Meier analyses
TitoFojoaRichard MSimonb
doi : 10.1016/S1470-2045(21)00473-3
Volume 22, Issue 10, October 2021, Pages 1358-1360
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial
AllanHackshawaChristine DBergb
doi : 10.1016/S1470-2045(21)00204-7
Volume 22, Issue 10, October 2021, Pages 1360-1362
Gestational trophoblastic neoplasia: one size does not fit all
EduardoPaulinoab
doi : 10.1016/S1470-2045(21)00399-5
Volume 22, Issue 10, October 2021, Page e420
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply
AntonioBragaabcRoss SBerkowitzdMichael JSeckle
doi : 10.1016/S1470-2045(21)00527-1
Volume 22, Issue 10, October 2021, Page e421
The CReDO workshop: a promising venture needing urgent reform
Gargi SSarodeaSachin CSarodea
doi : 10.1016/S1470-2045(21)00423-X
Volume 22, Issue 10, October 2021, Page e422
Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer
NaohiroOkanoaTomonoriMizutaniaFumioNagashimaaJunjiFurusea
doi : 10.1016/S1470-2045(21)00489-7
Volume 22, Issue 10, October 2021, Page e423
Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer – Authors' reply
XiaofeiZhuaYangsenCaoaHuojunZhanga
doi : 10.1016/S1470-2045(21)00529-5
Volume 22, Issue 10, October 2021, Page e424
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer
ElifHindiéa
doi : 10.1016/S1470-2045(21)00542-8
Volume 22, Issue 10, October 2021, Page e425
HER2-low-positive breast cancer from four neoadjuvant clinical trials
AbeidOmaraWaleedArafata
doi : 10.1016/S1470-2045(21)00456-3
Volume 22, Issue 10, October 2021, Page e426
HER2-low-positive breast cancer from four neoadjuvant clinical trials – Authors' reply
CarstenDenkertabValentinaNekljudovabSibylleLoiblcc
doi : 10.1016/S1470-2045(21)00548-9
Volume 22, Issue 10, October 2021, Page e427
Correction to Lancet Oncol 2020; 21: 271–82
doi : 10.1016/S1470-2045(21)00538-6
Volume 22, Issue 10, October 2021, Page e428
Correction to Lancet Oncol 2020; 21: 1465–77
doi : 10.1016/S1470-2045(21)00537-4
Volume 22, Issue 10, October 2021, Page e428
Correction to Lancet Oncol 2021; 22: 1301–11
doi : 10.1016/S1470-2045(21)00515-5
Volume 22, Issue 10, October 2021, Page e428
Developments in lung cancer biology in never-smokers
Talha KhanBurki
doi : 10.1016/S1470-2045(21)00532-5
Volume 22, Issue 10, October 2021, Page 1363
Artificial intelligence and cancer diagnosis: caution needed
PriyaVenkatesan
doi : 10.1016/S1470-2045(21)00533-7
Volume 22, Issue 10, October 2021, Page 1364
2021 World Conference on Lung Cancer
AllisonLandman
doi : 10.1016/S1470-2045(21)00547-7
Volume 22, Issue 10, October 2021, Page e429
Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?
Max SManoab
doi : 10.1016/S1470-2045(21)00285-0
Volume 22, Issue 10, October 2021, Pages 1365-1366
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
AdamFundytusMDabProfManjuSengarMDdDorothyLombeMDeWilmaHopmanMSccMatthewJalinkMScaBishalGyawaliMDabcDarioTrapaniMDfFelipeRoitbergPhDgProfElisabeth G EDe VriesMDiLorenzoMojaMDhAndréIlbawiMDhProfRichardSullivanPhDjProfChristopher MBoothMDabc
doi : 10.1016/S1470-2045(21)00463-0
Volume 22, Issue 10, October 2021, Pages 1367-1377
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
ProfPhilippeMoreauMDaCyrilleHulinMDbAurorePerrotMDcProfBertrandArnulfMDdKarimBelhadjMDeLotfiBenboubkerMDfProfMarie CBénéPhDgProfSonjaZweegmanMDiHélèneCaillonPharmDhDenisCaillotMDjJillCorreMDkProfMichelDelforgeMDlThomasDejoiePharmDhChantalDoyenMDmThierryFaconMDnCécileSonntagMDoJeanFontanMDpMohamadMohtyMDpKon-SiongJieMDqLionelKarlinMDrFrédériqueKuhnowskiMDsJérômeLambertMDtProfXavierLeleuMDuMargaretMacroMDvFrédériqueOrsini-PiocelleMDxMurielleRousselMDyAnne-MarieStoppaMDzProfNiels W C Jvan de DonkMDiSorayaWuillèmePharmDgAnnemiekBroijlMDaaCyrilleTouzeauMDaMouradTiabMDabProfJean-PierreMarolleauMDacProfNathalieMeulemanMDadMarie-ChristianeVekemansMDaeMatthijsWestermanMDafSaskia KKleinMDagMark-DavidLevinMDahProfFritzOffnerMDaiMartineEscoffre-BarbeMDajJean-RichardEveillardMDakRédaGaridiMDalTahamtanAhmadiMDamMariaKrevvataPhDanKeZhangPhDaoCarlade BoerPhDapSanjayVaraPhDaqTobiasKampfenkelMDapVeroniqueVanquickelberghePhDarJessicaVermeulenMDapProfHervéAvet-LoiseauMDkProfPieterSonneveldMDaa
doi : 10.1016/S1470-2045(21)00428-9
Volume 22, Issue 10, October 2021, Pages 1378-1390
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
Matthew SDavidsMDa†Benjamin LLampsonMDa†SvitlanaTyekuchevaPhDbcZixuWangMSbcJessica CLowneyBSaSamanthaPazienzaBSaJosieMontegaardNPaVictoriaPattersonRNaMatthewWeinstockMDdJennifer LCrombieMDaSamuel YNgMDaAustin IKimMDaCaron AJacobsonMDaAnn SLaCasceMDaPhilippeArmandMDaJon EArnasonMDdDavid CFisherMDaProfJennifer RBrownMDa
doi : 10.1016/S1470-2045(21)00455-1
Volume 22, Issue 10, October 2021, Pages 1391-1402
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
Stephen JSchusterMDaConstantine STamMDbPeterBorchmannMDcNinaWorelMDdJoseph PMcGuirkDOeHaraldHolteMDfEdmund KWallerMDgSamanthaJaglowskiMDhMichael RBishopMDiLloyd EDamonMDjStephen RonanFoleyMDkJason RWestinMDlIsabelleFleuryMDmP JoyHoMBBSnStephanMielkeMDopqTakanoriTeshimaMDrMuraliJanakiramMDsJing-MeiHsuMDtKojiIzutsuMDuMarie JoséKerstenMDvMonalisaGhoshMDwNinaWagner-JohnstonMDxKojiKatoMDyPaoloCorradiniMDzMarcelaMartinez-PrietoMDaaXiaHanMSaaRanjanTiwariMScabGillesSallesMDacRichard TMaziarzMDad
doi : 10.1016/S1470-2045(21)00375-2
Volume 22, Issue 10, October 2021, Pages 1403-1415
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
SheenaMukkadaMDaNickhillBhaktaMDaGuillermo LChantadaMDbYichenChenPhDaYuvaneshVedarajuMSaLaneFaughnanBSNaMaysam RHomsiMPHaHilmarieMuniz-TalaveraPhDaRadhikeshRanadiveMSaProfMonikaMetzgerMDaPaolaFriedrichMDaAsyaAgulnikMDaProfSimaJehaMDaCatherineLamMDaProfRashmiDalviMDcProfLailaHessissenMDdDaniel CMoreiraMDaProfVictor MSantanaMDaProfMichaelSullivanMDeProfEricBouffetMDfProfMiguela ACanizaMDaProfMeenakshiDevidasPhDaProfKathyPritchard-JonesMDgProfCarlosRodriguez-GalindoMDaon behalf of the
doi : 10.1016/S1470-2045(21)00454-X
Volume 22, Issue 10, October 2021, Pages 1416-1426
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis
Zachary JWardPhDaMagdalenaWalbaumMScdBenjaminWalbaumMDeMaria JoseGuzmanMDgProfJorgeJimenez de la JaraMDfBrunoNerviMDeProfRifatAtunFRCPbc
doi : 10.1016/S1470-2045(21)00426-5
Volume 22, Issue 10, October 2021, Pages 1427-1437
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
CarminePintoMDa†Paolo AndreaZucaliMDbc†MariaPaganoMDaFedericaGrossoMDdeGiuliaPaselloMDfgMarina ChiaraGarassinoMDhMarcelloTiseoMDijHectorSoto ParraMDkFrancescoGrossiMDlmFedericoCappuzzoMDnFilippode MarinisMDoPaoloPedrazzoliMDpqMariaBonomiMDrsLetiziaGianoncelliMDrtMatteoPerrinoMDcArmandoSantoroMDbcFrancescaZanelliMDaCandidaBonelliMDaAntonioMaconiMDeStefanoFregaMDgErikaGervasiMDaLucaBoniMDuGiovanni LucaCeresoliMDr
doi : 10.1016/S1470-2045(21)00404-6
Volume 22, Issue 10, October 2021, Pages 1438-1447
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery
ProfJoe YChangMDaProfReza JMehranMDbLeiFengMScVivekVermaMDaProfZhongxingLiaoMDaJames WWelshMDaSteven HLinMDaProfMichael SO'ReillyMDaProfMelenda DJeterMDaProfPeter ABalterPhDdProfStephen EMcRaeMDeProfDonaldBerryPhDcProfJohn VHeymachMDfProfJack ARothMDb
doi : 10.1016/S1470-2045(21)00401-0
Volume 22, Issue 10, October 2021, Pages 1448-1457
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
LuciaDel MastroMDacMauroMansuttiMDdGiancarloBisagniMDeRiccardoPonzoneMDfgAntonioDurandoMDhLauraAmaducciMDiEnricoCampadelliMDiFrancescoCognettiMDjAntonioFrassoldatiMDkAndreaMichelottiMDlSilviaMuraMDmYleniaUrracciMDnGiovanniSannaMDoStefaniaGoriMDpProfSabinoDe PlacidoMDqOrnellaGarroneMDrAlessandraFabiMDsCarlaBaroneMDtStefanoTamberiMDiClaudiaBighinMDaFabioPuglisiMDuGabriellaMorettiMDeGraziaArpinoMDqProfAlbertoBallestreroMDcFrancescaPoggioMDaMatteoLambertiniMDacFilippoMontemurroMDfgPaoloBruzziMDbon behalf of theGruppo Italiano Mammella investigators†
doi : 10.1016/S1470-2045(21)00352-1
Volume 22, Issue 10, October 2021, Pages 1458-1467
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
ProfJuan WValleMDaProfArndtVogelMDbCrystal SDenlingerMDcAiwu RuthHeMDdProfLi-YuanBaiMDeProfRashidaOrlovaMDqProfEricVan CutsemMDfJorgeAdevaMDgProfLi-TzongChenMDhRadkaObermannovaMDiThomas JEttrichMDjJen-ShiChenMDkHarpreetWasanMDlAllicia CGirvanPhDmWeiZhangPhDmJiangangLiuMDmChunlaoTangPhDmPhilip JEbertPhDmAmitAggarwalPhDmSamuel CMcNeelyPhDmBrian AMoserMSmJoana MOliveiraPhDnRobertoCarlesiMDoRichard AWalgrenMDmProfDo-YounOhPhDp
doi : 10.1016/S1470-2045(21)00409-5
Volume 22, Issue 10, October 2021, Pages 1468-1482
Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment
EtienneLenglinéMDaJulienPeronPhDcAntoineVanierPhDdProfFrançoisGueyffierPhDefSergeKouzanMDgProfPatrickDufourMDhProfBernardGuillotMDiHuguesBlondonMDjProfMichelClanetPhDkProfPierreCochatPhDkFrançoiseDegosPhDkProfSylvieChevretPhDbMathildeGrandePharmDkJadePutzoluPharmDkTransparency Committee of the French National Authority for Health
doi : 10.1016/S1470-2045(21)00337-5
Volume 22, Issue 10, October 2021, Pages e430-e434
Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension
Timothy JKendallMDa*MaxRobinsonBDSb*Daniel JBrierleyBDScShujing JaneLimMDbDaniel JO'ConnorMDdProfAbeer MShaabanMDefIanLewisPhDgProfAn-WenChanMDhProfDavid JHarrisonMDiSPIRIT-Path group‡
doi : 10.1016/S1470-2045(21)00344-2
Volume 22, Issue 10, October 2021, Pages e435-e445
Late phase 1 studies: concepts and outcomes
Jose CarlosBenitezMDa*ArthurGeraudMDb*MatthieuTexierMDcProfChristopheMassardPhDbeProfAngeloPaciPhDdfProfJean-CharlesSoriaPhDbeProfBenjaminBessePhDae
doi : 10.1016/S1470-2045(21)00467-8
Volume 22, Issue 10, October 2021, Pages e446-e455
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
RifaquatRahmanMDaSteffenVentzPhDbJonMcDunnPhDdBillLouvPhDdIrmarieReyes-RiveraPhDeMei-Yin CPolleyPhDfFaharMerchantPhDgLauren EAbreyMDhJoshua EAllenPhDiLaura KAguilarMDjEstuardoAguilar-CordovaMDjDavidAronsJDkKirkTannerPhDkStephenBagleyMDlMustafaKhasrawMDmProfTimothyCloughesyMDnProfPatrick YWenMDcBrian MAlexanderMDao*LorenzoTrippaPhDb*
doi : 10.1016/S1470-2045(21)00488-5
Volume 22, Issue 10, October 2021, Pages e456-e465
Bilateral lower extremity induration in a patient with leiomyosarcoma
Michelle SLeeBAabConnie RShiMDbMadelineSauerBScAlvaro CLagaMDcJordanTaliaMDbVinod ENambudiriMDab
doi : 10.1016/S1470-2045(21)00469-1
Volume 22, Issue 10, October 2021, Page e466
